Atea Pharmaceuticals Secures Credit Facility for Up to $200 Million from Hercules Capital
Atea received $65 million at closing, while access to further funding depends on milestones, agreement terms or lender discretion.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Atea Pharmaceuticals (Nasdaq: AVIR) entered a credit facility with Hercules Capital for up to $200 million to support its antiviral programs. Atea received $65 million at closing; further funding depends on milestones, agreement terms or lender discretion. The facility matures in 60 months, with a 48-month interest-only period that can extend to 60 months upon a specified commercial milestone.
Atea expects existing cash and investments plus the initial borrowing to fund planned operations into mid-2028. It expects results from its second Phase 3 hepatitis C trial, C-FORWARD, in early Q1 2027 and plans a US marketing application for bemnifosbuvir/ruzasvir in mid-2027. Its US launch goal is 2028, if approved; the financing also supports its hepatitis E clinical program.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointCredit facility provides up to $200 million in financing, including $65 million received at closing. 58% of market cap
- Major pointAtea described Phase 3 C-BEYOND hepatitis C trial results as positive.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Atea expects existing resources plus initial borrowing to fund planned operations into mid-2028.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Atea plans a US marketing application for bemnifosbuvir/ruzasvir in mid-2027.
- Minor point. Forward-looking: it has not happened yet and may not happen.Atea expects second Phase 3 C-FORWARD trial results in early Q1 2027.
2 minor points
- Minor point. Forward-looking: it has not happened yet and may not happen.Atea targets a US bemnifosbuvir/ruzasvir launch in 2028, if approved.
- Minor point. Forward-looking: it has not happened yet and may not happen.Financing supports expanded commercial-related activities and advancement of Atea’s hepatitis E clinical program.
Negative
- Major pointBorrowing adds $65 million in debt under a facility with a 60-month maturity. 19% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Potential runway through profitability depends on additional borrowings, successful US launch and expected operating expenditures.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional up to $35 million requires achievement of a clinical milestone and applicable agreement terms.
- Minor point. Forward-looking: it has not happened yet and may not happen.Additional up to $70 million requires regulatory, financing and commercial milestones and applicable agreement terms.
- Minor point. Forward-looking: it has not happened yet and may not happen.An additional $30 million may be available on request, at lenders’ sole discretion.
- Minor point. Forward-looking: it has not happened yet and may not happen.The 48-month interest-only period extends to 60 months only upon a specified commercial milestone.
Key Figures
- Maximum credit facility
- Up to $200 million
- Credit facility agreement
- Funding at closing
- $65 million
- Received under the facility at closing
- Clinical milestone funding
- Up to $35 million
- Conditional additional borrowing
- Regulatory, financing and commercial milestone funding
- Up to $70 million
- Conditional additional borrowing
- Lender-discretionary funding
- Up to $30 million
- May be available upon Atea's request, at lenders' discretion
- Facility maturity
- 60 months
- Facility term
- Interest-only period
- 48 months
- May be extended to 60 months upon a specified commercial milestone
- Planned cash runway
- Into mid-2028
- Based on current cash, cash equivalents and investments plus the initial facility funding
Key Terms
credit facility financial
non-dilutive financing financial
new drug application regulatory
hcv medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to
“Building on the positive Phase 3 C-BEYOND trial results for BEM/RZR in HCV, we expect several major milestones in 2027, including the topline results from our second Phase 3 trial, C-FORWARD, in early Q1 2027 and a planned new drug application (NDA) submission to the US Food and Drug Administration seeking marketing approval in mid-2027,” said Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea Pharmaceuticals. “This non-dilutive financing enhances our financial flexibility, while preserving a disciplined approach to capital deployment, allowing us to access capital in alignment with our progress toward our goal of product launch of BEM/RZR in the US in 2028 and a path toward profitability.”
“Atea is approaching several important clinical and regulatory milestones led by its global Phase 3 HCV program,” said R. Bryan Jadot, Senior Managing Director and Group Head of Life Sciences at Hercules Capital. “We are pleased to provide a flexible financing solution that supports the Company’s advancement and its efforts for the potential commercialization of BEM/RZR in the US market. We look forward to partnering with Atea as it advances its programs and prepares for future value-creating milestones.”
Under the agreement, Atea received
As of June 30, 2026, Atea had cash, cash equivalents and investments of
Additional information regarding the financing agreement will be disclosed a Current Report on Form 8-K filed with the Securities and Exchange Commission.
Morgan Stanley & Co. LLC served as the exclusive financial advisor to Atea on the credit facility.
About the C-BEYOND and C-FORWARD Phase 3 Trials in Adults with Chronic HCV
The global Phase 3 program is evaluating the fixed-dose combination (FDC) of BEM/RZR for the treatment of chronic HCV in patients with and without compensated cirrhosis. The program consists of two open-label controlled trials, which have collectively enrolled over 1,760 treatment-naïve patients: C-BEYOND (NCT06868264) in North America and C-FORWARD (NCT07037277) outside North America. The trials compare the FDC regimen of bemnifosbuvir (BEM), a nucleotide analog polymerase inhibitor, and ruzasvir (RZR), an NS5A inhibitor, to the FDC regimen of SOF/VEL. The regimen of BEM/RZR is administered orally once daily for eight weeks (in patients without cirrhosis) or 12 weeks (in patients with compensated cirrhosis), while the regimen of SOF/VEL is administered orally once daily for 12 weeks to all patients, with or without compensated cirrhosis.
The primary endpoint for each trial is HCV RNA below the lower limit of quantitation (LLOQ) at 24 weeks from the start of treatment; this endpoint encompasses sustained virologic response at 12 weeks post-treatment (SVR12) in each arm. SVR12 is the accepted definition of cure for HCV. Measuring the endpoint at 24 weeks from the start of treatment ensures that it is assessed at the same relative time from treatment initiation for all patients. In C-BEYOND, the primary endpoint was assessed in the mITT population, which comprises all patients who received at least one dose of the regimen and includes patients who discontinued early or were lost to follow-up. The mITT analysis as the primary analysis of the endpoint is aligned with the FDA.
Atea reported positive topline results from C-BEYOND, the Company’s Phase 3 trial in North America, with the regimen of bemnifosbuvir/ruzasvir (BEM/RZR) demonstrating statistical non-inferiority to Epclusa® (sofosbuvir/velpatasvir; SOF/VEL) in patients with hepatitis C virus (HCV), meeting the primary and secondary endpoints.
About Atea Pharmaceuticals
Atea is a late-stage clinical biopharmaceutical company focused on discovering, developing and commercializing oral antiviral therapies to address the unmet medical needs of patients with serious viral infections. Leveraging Atea’s deep understanding of antiviral drug development, nucleos(t)ide chemistry, biology, biochemistry and virology, Atea has built a proprietary nucleos(t)ide prodrug platform to develop novel product candidates to treat ssRNA viruses, which are a prevalent cause of serious viral diseases. Atea plans to continue to build its pipeline of antiviral product candidates by augmenting its nucleos(t)ide platform with other classes of antivirals that may be used in combination with its nucleos(t)ide product candidates. The Company is advancing its global Phase 3 program evaluating the regimen of BEM/RZR, which has the potential for a best-in-class profile, for the treatment of HCV. Atea is also advancing a Phase 1 program evaluating AT-587, which has the potential to become a first-in-class treatment for HEV. For more information, please visit www.ateapharma.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to statements regarding the length of Atea’s cash runway including potential to achieve profitability, future operating expenditures, its ability to access and draw additional amounts under and satisfy conditions of the credit facility, the anticipated uses of proceeds, the potential best-in-class profile of the BEM/RZR regimen for the treatment of HCV, the potential to develop a first in class product for the treatment of HEV, anticipated milestone events and timelines including the timeline for readout of the C-FORWARD Phase 3 clinical trials results, potential submission of an NDA for US marketing approval of BEM/RZR, potential approval and commercial launch of BEM/RZR, future results of operations and business strategy. When used herein, words including “expected,” “should,” “anticipated,” “believe,” “will,” “plans”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Atea’s current expectations and various assumptions. Atea believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Atea may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, uncertainties inherent in the drug discovery and development process and the regulatory submission or approval process, unexpected or unfavorable safety or efficacy data or results observed during clinical trials or in data readouts; delays in or disruptions to clinical trials or our business; our reliance on third parties over which we may not always have full control; risks related to our outstanding debt; our ability to manufacture sufficient commercial product; competition from approved treatments for HCV; dependence on the success of Atea’s most advanced product candidates, in particular the BEM/RZR regimen for the treatment of HCV; as well as the other important factors discussed under the caption “Risk Factors” in Atea’s Annual Report on Form 10-Q for the quarterly period ended June 30, 2026 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. All forward-looking statements represent management’s estimates as of the date of this press release. While Atea may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. Forward-looking statements should not be relied upon as representing Atea’s views as of any date subsequent to the date of this press release.
Contacts
Jonae Barnes
SVP, Investor Relations and Corporate Communications
617-818-2985
barnes.jonae@ateapharma.com
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much financing did Atea secure from Hercules Capital?
Atea secured a credit facility for up to $200 million and received $65 million at closing. Additional funding includes up to $35 million tied to a clinical milestone, up to $70 million tied to regulatory, financing and commercial milestones, and $30 million that may be available at lenders’ sole discretion.
How long does Atea expect its cash to last after the Hercules financing?
Atea expects its current cash, cash equivalents and investments, together with the initial $65 million borrowing, to fund planned operations into mid-2028 under its current operating plan. Additional conditional borrowings could potentially extend runway through profitability, assuming a successful US launch of bemnifosbuvir/ruzasvir and its current expectations for future operating expenditures.